BNA Books, a division of US-based specialised news and information publisher BNA, has announced the publication of the 2011 Supplement to Pharmaceutical Law: Regulation of Research, Development, and Marketing. The supplement seeks to provide important updates on securities cases and developments involving fraud and abuse, Health Insurance Portability and Accountability Act (HIPAA) and the Food and Drug Administration (FDA). The treatise is one of the many ABA/BNA publications available from BNA Books.
Pharmaceutical Law: Regulation of Research, Development, and Marketing claims to be the only resource available that provides expert commentary and authoritative insights into a comprehensive range of pharmaceutical law issues. The publication is said to offer the information required by transactional healthcare attorneys to adequately advise clients on the opportunities and the liabilities in this industry. It addresses the considerable fraud-and-abuse risks unique to this submarket of the healthcare industry; covers off-label marketing-selling a drug for a purpose other than its intended use; and explains and discusses other hot risks areas, including the potential for antitrust, securities law and other compliance violations.
The treatise was published in cooperation with the ABA Health Law Section. Section publications seek to provide a balanced forum for the views and professional development of practitioners in health law.
The editor-in-chief of Pharmaceutical Law: Regulation of Research, Development, and Marketing, 2011 Supplement is Michael E. Clark, Special Counsel, with Duane Morris, LLP, Houston, and Adjunct Professor of Law at the University of Houston Law Center.
To access our daily STM news feed through your iPhone, iPad, or other smartphones, please visit www.myscoope.com for a mobile friendly reading experience.
